RhumbLine Advisers’s Stoke Therapeutics STOK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $754K | Buy |
66,419
+16,820
| +34% | +$191K | ﹤0.01% | 2395 |
|
|
2025
Q1 | $330K | Buy |
49,599
+225
| +0.5% | +$1.5K | ﹤0.01% | 2830 |
|
|
2024
Q4 | $545K | Buy |
49,374
+2,787
| +6% | +$30.7K | ﹤0.01% | 2629 |
|
|
2024
Q3 | $573K | Sell |
46,587
-1,273
| -3% | -$15.6K | ﹤0.01% | 2614 |
|
|
2024
Q2 | $647K | Buy |
47,860
+5,990
| +14% | +$80.9K | ﹤0.01% | 2483 |
|
|
2024
Q1 | $565K | Buy |
41,870
+899
| +2% | +$12.1K | ﹤0.01% | 2590 |
|
|
2023
Q4 | $215K | Sell |
40,971
-38
| -0.1% | -$200 | ﹤0.01% | 3156 |
|
|
2023
Q3 | $162K | Sell |
41,009
-1,166
| -3% | -$4.59K | ﹤0.01% | 3267 |
|
|
2023
Q2 | $448K | Buy |
42,175
+7,578
| +22% | +$80.6K | ﹤0.01% | 2756 |
|
|
2023
Q1 | $288K | Buy |
34,597
+406
| +1% | +$3.38K | ﹤0.01% | 2627 |
|
|
2022
Q4 | $316K | Buy |
34,191
+475
| +1% | +$4.39K | ﹤0.01% | 2660 |
|
|
2022
Q3 | $433K | Buy |
33,716
+1,865
| +6% | +$24K | ﹤0.01% | 2561 |
|
|
2022
Q2 | $421K | Buy |
31,851
+12,506
| +65% | +$165K | ﹤0.01% | 2585 |
|
|
2022
Q1 | $407K | Buy |
19,345
+1,362
| +8% | +$28.7K | ﹤0.01% | 2512 |
|
|
2021
Q4 | $431K | Sell |
17,983
-336
| -2% | -$8.05K | ﹤0.01% | 2570 |
|
|
2021
Q3 | $466K | Buy |
18,319
+849
| +5% | +$21.6K | ﹤0.01% | 2578 |
|
|
2021
Q2 | $588K | Buy |
17,470
+1,963
| +13% | +$66.1K | ﹤0.01% | 2495 |
|
|
2021
Q1 | $602K | Sell |
15,507
-165
| -1% | -$6.41K | ﹤0.01% | 2404 |
|
|
2020
Q4 | $971K | Buy |
15,672
+910
| +6% | +$56.4K | ﹤0.01% | 2141 |
|
|
2020
Q3 | $494K | Sell |
14,762
-2,115
| -13% | -$70.8K | ﹤0.01% | 2295 |
|
|
2020
Q2 | $402K | Sell |
16,877
-3,341
| -17% | -$79.6K | ﹤0.01% | 2441 |
|
|
2020
Q1 | $463K | Buy |
20,218
+12,279
| +155% | +$281K | ﹤0.01% | 2195 |
|
|
2019
Q4 | $225K | Buy |
+7,939
| New | +$225K | ﹤0.01% | 2711 |
|